Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells

International Journal of Oncology

Volumn 31, Issue 5, 2007, Pages 1111-1117

  Zhen, Hai Ning ^a   Li, Li Wen ^b   Zhang, Wei ^a   Fei, Zhou ^a   Shi, Chang Hong ^a   Yang, Tong Tao ^a   Bai, Wen Tao ^a   Zhang, Xiang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

Author keywords

Angiogenesis; Glioma; Growth; Short hairpin RNA; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; FEMALE; GENETICS; GLIOMA; HUMAN; MITOSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLIOMA; HUMANS; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; MITOSIS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING;

EID: 38449106717     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Brown JM and Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5: 231-237, 2005.
2. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
3. Wright CW and Duckett CS: Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 115: 2673-2678, 2005.
4. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
5. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003.
6. Li F and Brattain MG: Role of the survivin gene in pathophysiology. Am J Pathol 169: 1-11, 2006.
7. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM and Ryan BM: Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60, 2007.
8. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T and Noel JP: Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 7: 602-608, 2000.
9. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK and Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123, 2001.
10. O'Connor DS, Wall NR, Porter AC and Altieri DC: A p34 (cdc2) survival checkpoint in cancer. Cancer Cell 2: 43-54, 2002.
11. Sun C, Nettesheim D, Liu Z and Olejniczak ET: Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 44: 11-17, 2005.
12. Vong QP, Cao K, Li HY, Iglesias PA and Zheng Y: Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310: 1499-1504, 2005.
13. Vader G, Kauw JJ, Medema RH and Lens SM: Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 7: 85-92, 2006.
14. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation. Oncogene 19: 3225-3234, 2000.
15. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC and Altieri DC: Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 158: 1757-1765, 2001.
16. Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99: 4349-4354, 2002.
17. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC and Altieri DC: Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 8: 987-994, 2002.
18. McKay TR, Bell S, Tenev T, Stoll V, Lopes R, Lemoine NR and McNeish IA: Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene 22: 3539-3547, 2003.
19. Kanwar JR, Shen WP, Kanwar RK, Berg RW and Krissansen GW: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93: 1541-1552, 2001.
20. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809, 2000.
21. Leech SH, Olie RA and Zangemeister-Wittke U: Use of antisense oligonucleotides for therapy. Manipulation of apoptosis inhibitors for destruction of lung cancer cells. Methods Mol Med 75: 655-670, 2003.
22. Pennati M, Colella G, Folini M, Citti L, Daidone MG and Zaffaroni N: Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 109: 285-286, 2002.
23. Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG and Zaffaroni N: Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23: 386-394, 2004.
24. Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP and Meye A: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065-1071, 2004.
25. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y and Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107: 746-756, 2006.
26. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006.
27. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20: 1063-1068, 2002.
28. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K and Kurisu K: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077-1083, 2003.
29. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K and Miyatake S: Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99: 738-745, 2003.
30. Jiao BH, Yao ZG, Geng SM and Zuo SH: Expression of survivin, a novel apoptosis inhibitor and cell cycle regulatory protein, in human gliomas. Chin Med J (Engl) 117: 612-614, 2004.
31. Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, Fu LA, He XS, Ma FC and Wang XL: Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104: 2775-2783, 2005.
32. Mittal V: Improving the efficiency of RNA interference in mammals. Nat Rev Genet 5: 355-365, 2004.
33. Stevenson M: Therapeutic potential of RNA interference. N Engl J Med 351: 1772-1777, 2004.
34. Shankar P, Manjunath N and Lieberman J: The prospect of silencing disease using RNA interference. JAMA 293: 1367-1373, 2005.
35. Moffat J and Sabatini DM: Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol 7: 177-187, 2006.
36. Kim DH and Rossi JJ: Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184, 2007.
37. Banks DP, Plescia J, Altieri DC, Chen J, Rosenberg SH, Zhang H and Ng SC: Survivin does not inhibit caspase-3 activity. Blood 96: 4002-4003, 2000.
38. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H and Hamada H: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10: 162-171, 2004.
39. Temme A, Herzig E, Weigle B, Morgenroth A, Schmitz M, Kiessling A, Rieger MA, Schackert HK and Rieber EP. Inhibition of malignant glioma cell growth by a survivin mutant retrovirus. Hum Gene Ther 16: 209-222, 2005.